Alendronate 70 mg once weekly vs. placebo: Tolerability study in patients with osteoporosis.

被引：0
作者：
Greenspan, SL
Field-Munves, EM
Tonino, RP
Mako, B
Smith, ME
Yates, J
Palmisano, J
机构：
[1] Oteoporosis Prevent & Treatment Ctr, Pittsburgh, PA USA
[2] Springhouse Profess Ctr, Allentown, PA USA
[3] Good Hlth, Burlington, VT USA
[4] Merck & Co Inc, W Point, PA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2001年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S405 / S405
页数：1
相关论文
共 50 条
  • [31] The effectiveness of alendronate (70 mg weekly) in women with postmenopausal osteoporosis
    Martchenkova, L. A.
    Dreval, A. V.
    Kryukova, I. V.
    Tishenina, R. S.
    Milov, N. M.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S44 - S44
  • [32] Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis
    Rizzoli, R
    Roux, C
    Greenspan, S
    Bone, H
    Schnitzer, T
    Watts, N
    Adami, S
    Foldes, J
    Uebelhart, B
    Peverly, C
    Santora, A
    Kaur, A
    Wu, M
    Orloff, J
    BONE, 2001, 28 (05) : S94 - S94
  • [33] Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis
    Rizzoli, R
    Roux, C
    Greenspan, S
    Bone, H
    Schnitzer, T
    Watts, N
    Adami, S
    Uebelhart, B
    Foldes, J
    Peverly, C
    Santora, A
    Kaur, A
    Wu, M
    Orloff, J
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 25 - 25
  • [34] The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis
    Yuxiang Yan
    Wei Wang
    Hanmin Zhu
    Mei Li
    Jianli Liu
    Bangyao Luo
    Haibao Xie
    Guangjian Zhang
    Fuobao Li
    Journal of Bone and Mineral Metabolism, 2009, 27 : 471 - 478
  • [35] Patients with osteoporosis prefer once weekly to once daily dosing with alendronate
    Kendler, D
    Kung, AWC
    El-Hajj Fuleihan, G
    González, JGG
    Gaines, KA
    Verbruggen, N
    Melton, ME
    MATURITAS, 2004, 48 (03) : 243 - 251
  • [36] The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: A placebo-controlled endoscopy study
    Lanza, F
    Sahba, B
    Schwartz, H
    Winograd, S
    Torosis, J
    Quan, H
    Reyes, R
    Musliner, T
    Daifotis, A
    Leung, A
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (01) : 58 - 64
  • [37] Safety of once-weekly alendronate 70 mg in periodontal disease
    Van Dyke, T
    Ryder, M
    Cordero, R
    Gallagher, A
    Griffiths, G
    Offenbacher, S
    Cizza, G
    Kimberlin, M
    Lombardi, A
    Meng, L
    Shih, W
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 26 - 26
  • [38] Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis
    Greenspan, SL
    Bone, G
    Schnitzer, TJ
    Watts, NB
    Adami, S
    Foldes, AJ
    Roux, C
    Levine, MA
    Uebelhart, B
    Santora, AC
    Kaur, A
    Peverly, CA
    Orloff, JJ
    Rizzoli, R
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (11) : 1988 - 1996
  • [39] Once-weekly alendronate: Two year subgroup efficacy analyses in postmenopausal women with osteoporosis.
    Bone, H
    Felsenberg, D
    Greenwald, M
    Schnitzer, T
    Kaur, A
    Cudny, M
    Peverly, C
    Orloff, J
    Santora, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S526 - S526
  • [40] Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study
    Shinji Uchida
    Tadaaki Taniguchi
    Takafumi Shimizu
    Taro Kakikawa
    Kotoba Okuyama
    Masahiko Okaniwa
    Hironori Arizono
    Koichi Nagata
    Arthur C. Santora
    Masataka Shiraki
    Masao Fukunaga
    Tatsushi Tomomitsu
    Yasuo Ohashi
    Toshitaka Nakamura
    Journal of Bone and Mineral Metabolism, 2005, 23 : 382 - 388
12345